Last Update

2015-06-01T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Lloyd Kasper?

Dr. Lloyd H. Kasper MD

Immunologist and Neurologist

Geisel School of Medicine at Dartmouth

Direct Phone: (866) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Geisel School of Medicine at Dartmouth

One Medical Center Dr (HB 7070)

Lebanon, New Hampshire 03756

United States

Find other employees at this company (435)

Background Information

Employment History

Principal Investigator

Dartmouth College

Speaker, Teva Neuroscience, Bayer

Teva Neuroscience , Inc.

Consultant

EMD Serono , Inc.

Director of the Multiple Sclerosis Center

DHMC

Affiliations

Co-Founder
Symbiotix Inc

Advisory Board Member
Prime Inc

Education

M.D.

MD

Dartmouth University

Web References (65 Total References)


Lloyd H Kasper

www.psychosomatic.org [cached]

Dr. Lloyd Kasper

...
Lloyd H Kasper, MD
Dr. Lloyd Kasper is a Professor of Immunology/Microbiology and Medicine at Geisel School of Medicine where he has been actively involved in basic and applied immunology supported by research grants from the National Institutes of Health, March of Dimes, National Multiple Sclerosis Society and industry. He established and directed the Dartmouth MS Center for over 20 years. His basic research interests are related to understanding immunopathogenesis of CNS demyelinating disease, the role of specific immune regulatory populations in disease control and the role of the gut microbiome in CNS demyelination. Dr. Kasper has authored over 175 research and clinical articles related to these interests. He has been the primary organizer for several Keystone Symposia most recently the Microbiome: Effector/Regulatory Networks. When not doing science at Dartmouth, Kasper can be found painting in his studio in Taos, New Mexico.


Biosciences « B2B News

www.tizinc.com [cached]

Symbiotix' lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.

PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.
"Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability. However, all of these FDA-approved treatments have side effects some of which can be rather profound," said Prof. Kasper. "We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis.


Biosciences « B2B News

pr.tizinc.com [cached]

Symbiotix' lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.

PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.
"Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability. However, all of these FDA-approved treatments have side effects some of which can be rather profound," said Prof. Kasper. "We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis.


Symbiotix Biotherapies Announces $2.3 Million Award from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) « B2B News

www.tizinc.com [cached]

Symbiotix' lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.

PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.
"Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability. However, all of these FDA-approved treatments have side effects some of which can be rather profound," said Prof. Kasper. "We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis.


The study adds more evidence that ...

www.msdiscovery.org [cached]

The study adds more evidence that "bacteria have the capacity in and of themselves to modulate the immune system and make it respond in a positive way," said Lloyd Kasper, M.D., an immunologist and neurologist at Geisel School of Medicine at Dartmouth College in New Hampshire, who was not involved in the study.

The experiments did not use an MS model, but in an interview with the MS Discovery Forum (MSDF), Kasper speculated that the bacteria metabolites might have a similar effect in mouse models of MS. Three years ago, Kasper's team reported that a molecule on the surface of one common species of gut bacteria (Bacteroides fragilis) protected against central nervous system demyelinating disease in two experimental autoimmune encephalomyelitis mouse models, apparently by turning on Tregs, both prophylactically and therapeutically (Ochoa-Repáraz, et al., 2010).
...
Similar caveats apply to all work on how the microbiome affects immune function, Kasper and Mazmanian said.

Similar Profiles

Other People with this Name

Other people with the name Kasper

Barbara Kasper
Bethel Lutheran Church

Erica Kasper
Central California Faculty Medical Group, Inc.

Kelly Kasper
American Red Cross Serving King & Kitsap Counties

Thomas Kasper

Sherri Kasper
//www.southwoodanimalhospital.com/

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory